Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
develops and commercializes medical devices for structural heart disease treatment, focusing on transcatheter mitral valve repair.
Hanyu Medical, a Shanghai, China-based organization, specializes in developing and commercializing innovative medical devices for structural heart disease treatment, with its flagship product, ValveClamp, providing minimally invasive transcatheter repair for mitral regurgitation. The company, founded in 2016 by CEO Dai Yufeng, has secured significant funding through six financing rounds, attracting investments from notable firms including Yunfeng Fund, Oriental Securities, and CITIC Industrial Fund. With a dedicated team of 10-50 employees, including a core R&D group of 38 led by CTO Tang Yushi, Hanyu Medical holds an impressive 111 patents related to its advanced medical technologies. In April 2021, the company submitted an IPO application to the Hong Kong Stock Exchange, with China International Capital Corporation and Citigroup serving as sponsors. Its prospectus was subsequently listed in September 2021 after passing the HKEX hearing, marking a key milestone for this venture capital-funded enterprise.
Hanyu Medical has raised $163.4M across 3 funding rounds.
Hanyu Medical has raised $163.4M in total across 3 funding rounds.
Hanyu Medical has raised $163.4M across 3 funding rounds. Most recently, it raised $76.9M Series D in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 15, 2021 | $76.9M Series D | Xiao (albert) Huang | Octagon Capital | Announced |
| Aug 13, 2020 | $72M Series D | — | — | Announced |
| Dec 28, 2018 | $14.6M Series B | — | — | Announced |
Hanyu Medical has raised $163.4M in total across 3 funding rounds.
Hanyu Medical's investors include Xiao (Albert) Huang, Octagon Capital.